Parvoduk
live attenuated Muscovy duck parvovirus
Table of contents
Overview
The marketing authorisation for Parvoduk has lapsed because it has not been marketed in the European Union in the three years following the granting of the authorisation.
Authorisation details
| Product details | |
|---|---|
| Name |
Parvoduk
|
| Agency product number |
EMEA/V/C/002740
|
| Active substance |
live attenuated Muscovy duck parvovirus
|
| International non-proprietary name (INN) or common name |
live attenuated Muscovy duck parvovirus
|
| Species |
Ducks
|
| Anatomical therapeutic chemical veterinary (ATCvet) codes |
QI01BD03
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
Merial
|
| Revision |
2
|
| Date of issue of marketing authorisation valid throughout the European Union |
11/04/2014
|
| Contact address |
29 Avenue Tony Garnier |
Product information
09/01/2019 Parvoduk - EMEA/V/C/002740 - R/0006
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
-
duck parvovirus
-
Live viral vaccines
-
Immunologicals for aves
Therapeutic indication
Active immunisation of ducks to prevent mortality1 and to reduce weight loss and lesions of duck parvovirosis and Derzsy's disease.
1In absence of maternally derived antibodies.